Control of Pain in Intravitreal Injections Using Topical NSAIDs

• Status: Completed
• Trial end date: 2019-12-19
• Target enrollment: 0
• Participant gender: All

Summary

Intravitreal injections (IVI) are a common form of treatment for multiple retinal pathologies. The investigators hypothesize that an intervention with a topical NSAID will alleviate pain experienced at intravitreal injection (IVI) and post-IVI. 46 participants will be recruited, randomized into 1 of 3 treatment arms, and can expect to be on study for a day.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Bromfenac; Lubricant Eye Drops

Criteria

Inclusion Criteria:

• Eyes with retinal pathology requiring anti-VEGF therapy

• Previously had an IVI

Exclusion Criteria:

• History of previous eye surgery other than cataract extraction

• Herpetic eye disease

• Uncontrolled glaucoma

• Uveitis

• Acute conjunctivitis

• Pregnancy

• Known previous adverse response or contraindication to intravitreal injection, Bromfenac, or other NSAIDs.

• Keratitis including povidone-induced keratitis

• Bullous keratopathy

• Diagnosis of dry eye syndrome

• Uncontrolled diabetes

• NSAID use 3 days prior to IVI